-
Shanghai Expert Consensus on the Clinical Application of Oncolytic Viruses in the Treatment of Malignant Tumors (Version 2021)-Summary
Time of Update: 2021-04-18
In clinical work, most physicians lack sufficient understanding of the mechanism of action of oncolytic virus drugs and evidence-based medicine, and the clinical application lacks a unified standard.
-
BeiGene announces the clinical data of Sitravatinib combined with Bazeran® at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Time of Update: 2021-04-18
Data from an ongoing phase 1b clinical trial of sitravatinib combined with Baizian® shows that the combination of drugs targets patients with unresectable or metastatic melanoma that is refractory or
-
Wei Xiawei's team from Sichuan University discovers a potential target for the treatment of lung cancer
Time of Update: 2021-04-18
The study found that the expression of CXCR2 in human lung cancer stroma and tumor cells is elevated, which is related to the prognosis of patients.
The study found that the expression of CXCR2 in human lung cancer stroma and tumor cells is elevated, which is related to the prognosis of patients.
-
There are differences between men and women: the fatter the men and the thicker the waist of women, the higher the risk of colorectal cancer!
Time of Update: 2021-04-18
Recently, researchers from the University of Bristol in the United Kingdom used a naturally occurring test called Mendelian randomization to use genetic information to better understand the causality of adjustable factors and studied two different measures of obesity-namely Whether body mass index (BMI) and waist-to-hip ratio (WHR) are associated with the risk of CRC in men and women, respectively.
-
Nature | Bacterial antigen peptides identified in melanoma provide a new mechanism for bacteria to affect immune system activation and anti-tumor treatment response
Time of Update: 2021-04-18
The researchers first performed 16S rRNA sequencing on 17 melanoma metastatic tumor samples from 9 patients and identified 41 types of bacteria, and the bacterial composition between different metastases of the same patient and tumors of different patients were highly similar.
-
Do HL patients with early poor prognosis need to receive intensive chemotherapy?
Time of Update: 2021-04-18
The HD14 trial is a randomized, international, multi-center phase III clinical study conducted by the German Hodgkin’s Lymphoma Research Group (GHSG) to evaluate the early poor prognosis of Hodgkin’s lymphoma (HL) patients receiving standard-intensity chemotherapy and Strengthen the efficacy and safety of chemotherapy.
-
BeiGene Announces Global Phase 3 Clinical Interim Analysis Results of Baizean® in the Treatment of Second- and Third-Line Non-Small Cell Lung Cancer
Time of Update: 2021-04-18
On April 13, BeiGene (Nasdaq code: BGNE; Hong Kong Stock Exchange code: 06160) announced its anti-PD-1 antibody Bazeran® at the American Association for Cancer Research (AACR) 2021 annual meeting (Tilelizumab) The interim analysis results of the global phase 3 clinical trial RATIONALE 303 compared with docetaxel for second-line or third-line locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.
-
No tumor cells were found in surgical specimens of nearly 1/4 patients. The world's first IO neoadjuvant phase III study confirmed that nivolumab combined with chemotherapy can significantly improve the pCR of lung cancer patients
Time of Update: 2021-04-18
At noon on the 10th, local time, Professor Patrick M Forde from Johns Hopkins Hospital reported that the primary endpoint of the Phase III CheckMate-816 study of immunocombined chemotherapy with neoadjuvant therapy that can cut non-small cell lung cancer (NSCLC) is pathological complete remission ( pCR) complete data.
-
Cancer Cell: p53 mutations affect natural immune signals and promote tumor immune escape
Time of Update: 2021-04-18
003 (Figure 1, p53 mutation inhibits the transmission of natural immune cells) In contrast to mtp53, shRNA was used to knock down the expression level of wild-type p53 in human lung cancer A549 cells, resulting in decreased phosphorylation of STING, TBK1 and IRF3.
-
Professor Miao Liyun: The remission rate of combined therapy is 72%!
Time of Update: 2021-04-18
Professor Miao Liyun pointed out, “From the perspective of indications, recombinant human endostatin has a wide range of options, and its combination with platinum-containing dual-drug chemotherapy The program has also been recommended by the "Chinese Expert Consensus on Anti-angiogenic Drugs for Advanced Non-small Cell Lung Cancer (2020 Edition)" [4].
-
The second domestic company, Junshi PD-1 urothelial carcinoma was approved for listing by NMPA
Time of Update: 2021-04-18
Two months ago, teriprizumab was approved for the second indication in China, the second-line treatment of patients with recurrent/metastatic nasopharyngeal carcinoma.
-
Oncolytic bacteria become a new direction for cancer immunotherapy!
Time of Update: 2021-04-18
The YB1 tumor-oriented drug delivery system of Hong Kong Oncolytic Biopharmaceuticals exerts its oncolytic effect in three stages after injection: 30 minutes after injection is the guidance period, at this stage YB1 can continuously scan the surrounding environment through its precise targeting Find the location of the tumor based on the oxygen concentration; if the tumor area is not found within 30 minutes, YB1 will start the self-destruction program, which will not cause damage to the body.
-
Cancer Cell: The molecular mechanism of key protein-mediated tumor immune tolerance
Time of Update: 2021-04-18
Therefore, targeting the STC1 protein on the surface of tumor cells can help reduce tumor immune evasion and resistance to immunotherapy.
023 Original source: Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.
-
The 2021 CSCO BC annual meeting was held smoothly, and consensus on multiple guidelines was issued, and highlights were revealed.
Time of Update: 2021-04-18
At the press conference of the 2021 National Breast Cancer Conference held in the evening, the high-profile "2021 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines" and "Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Clinical Diagnosis and Treatment Expert Consensus 2021" Edition", "Consensus of Chinese Experts on Breast Cancer Bone Metastasis" and "CSCO AI for BC 2021" artificial intelligence-assisted decision-making system updates have been released one after another.
-
The results of the first phase 3 study of the first-line immunotherapy for gastric cancer in China are announced, which is expected to revolutionize the treatment landscape
Time of Update: 2021-04-18
"The Bristol-Myers Squibb Company press release pointed out that in the clinical study of immunotherapy for gastric cancer and gastroesophageal junction cancer covering patients in mainland China, the CheckMate-649 study is the first and currently the only phase 3 study of first-line treatment with positive results.
-
Come on Monday to the CCR spirit one morning
Time of Update: 2021-04-18
The author mainly applied variable selection algorithm to screen prognostic-related genes, and through leave-one-out cross-validation, trained a random forest classifier based on the first 21 genes (BRAVO-DX).
-
The world's first phase III study of neoadjuvant therapy for lung cancer was successful!
Time of Update: 2021-04-18
Effective neoadjuvant immunotherapy can achieve MPR and even pCR, and improve the long-term prognosis (picture source: "Science") The prognosis of early NSCLC patients is relatively good, so if clinical research wants to collect PFS, OS and other efficacy data, long-term follow-up is necessary Like a study of neoadjuvant chemotherapy, it took 12 years from the beginning of the enrollment to the publication of the results [4].
-
The "three brothers" of Parkinson's disease, cancer, and type 2 diabetes are originally in the same line
Time of Update: 2021-04-18
Introduction: Enzymes that play a major role in cancer and type 2 diabetes can also activate the "clear" protein in Parkinson's disease.
It is surprising that only three participants (AMPK, ULK1, Parkin) initiated a process as important as mitochondrial phagocytosis, so that Shaw hardly believed it.
-
Pediatr Blood Cancer: Radiotherapy combined with VPA and bevacizumab in the treatment of glioma is well tolerated
Time of Update: 2021-04-17
In summary, the results of this study show that radiotherapy combined with VPA and bevacizumab is well tolerated, but it does not seem to improve EFS or OS in children with DIPG or HGG.
-
JAMA: The effect of celecoxib combined with FOLFOX standard adjuvant chemotherapy on the disease-free survival rate of colon cancer patients
Time of Update: 2021-04-17
Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .
